CD45RB Is a Novel Molecular Therapeutic Target to Inhibit Aβ Peptide-Induced Microglial MAPK Activation
2008
CD45RB as a Target to Inhibit Microglial Activation in Alzheimer's Disease
publication
Evidence: moderate
Author Information
Author(s): Zhu Yuyan, Hou Huayan, Nikolic William V., Ehrhart Jared, Rrapo Elona, Bickford Paula, Giunta Brian, Tan Jun
Primary Institution: University of South Florida College of Medicine
Hypothesis
CD45RB modulation can inhibit Aβ peptide-induced microglial activation.
Conclusion
CD45RB cross-linking enhances microglial phagocytosis of Aβ1–42 peptide while reducing neurotoxic inflammation.
Supporting Evidence
- CD45RB cross-linking enhances microglial phagocytosis of Aβ1–42 peptide.
- Inhibition of p38 MAPK increases microglial phagocytosis of Aβ.
- Cross-linking CD45RB reduces TNF-α and IL-6 release in microglial cells.
Takeaway
This study shows that a specific protein can help brain cells clean up harmful substances while reducing inflammation, which might help treat Alzheimer's disease.
Methodology
Microglial cells were treated with Aβ peptides and CD45 isoform agonist antibodies to assess phagocytosis and MAPK pathway activation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website